While HIF2A gain tumours exhibited very few alterations in immune scores, HIF1A loss tumours showed statistically significant increases or decreases in 57 of 83 immune signatures of a variety of lymphoid and myeloid lineage cells. The gene discussed is HIF1A; the disease is neoplasm.